Leadership Overview
Gufic Group has 6 executives leading key functions including operations, finance, human resources, sales, marketing, and strategic development.
Driven by a commitment to advancing healthcare, Gufic Group is dedicated to producing high-quality pharmaceutical and herbal products, including a significant volume of lyophilized injections, serving major hospital networks across India and expanding its global reach through continuous research and development.
Driven by a commitment to advancing healthcare, Gufic Group is dedicated to producing high-quality pharmaceutical and herbal products, including a significant volume of lyophilized injections, serving major hospital networks across India and expanding its global reach through continuous research and development.
Leadership Roles at Gufic Group
Devkinandan Roonghta - Chief Financial Officer
Devkinandan Roonghta, the Chief Financial Officer at Gufic Group, manages all financial strategies and operations, ensuring fiscal health and sustainable growth. Roonghta oversees budgeting, financial planning, and investment strategies, aligning financial objectives with the company's broader mission of delivering innovative pharmaceutical and herbal products. This critical role involves managing capital allocation for research and development initiatives, supporting the continuous launch of advanced new products, and facilitating the expansion of Gufic Group's international market presence. Devkinandan Roonghta's financial acumen is essential for maintaining the company's status as a major manufacturer of lyophilized injections and for supporting its extensive network supplying hospital chains across India. By providing robust financial oversight, the CFO enables strategic decision-making, optimizes resource utilization, and ensures compliance with all financial regulations. Roonghta's leadership directly contributes to the company's long-term profitability and its capacity for ongoing investment in product development and market expansion.
Nagesh Yarrabathina - Chief Operating Officer
Nagesh Yarrabathina, the Chief Operating Officer at Gufic Group, directs all operational facets of the pharmaceutical manufacturing business. Overseeing the production of a diverse range of products, including antibiotics, antifungals, and antiviral treatments, Yarrabathina ensures the consistent output of high-quality pharmaceutical and herbal goods. This leadership role involves managing the large-scale manufacturing of lyophilized injections, a core competency for Gufic Group, and optimizing supply chain logistics to meet demand from major hospital chains and leading medical facilities across India. By focusing on operational efficiency and stringent quality control, Nagesh Yarrabathina drives the company's ability to deliver essential medicines. The COO's responsibilities extend to coordinating production schedules, managing plant operations, and implementing process improvements to enhance manufacturing capabilities and support the company's expanding international footprint. This strategic oversight ensures Gufic Group maintains its position as a leading pharmaceutical manufacturer.
Shekhar Aley - President, Sales & Marketing-Critical Care Sbus Indianepalinneurocare
Shekhar Aley, the President, Sales & Marketing-Critical Care Sbus Indianepalinneurocare at Gufic Group, drives the commercial strategy for critical care business units across India, Nepal, and neurocare markets. Aley spearheads sales and marketing initiatives, focusing on expanding the reach of Gufic Group's innovative pharmaceutical and herbal products, including its extensive range of lyophilized injections. This role involves cultivating strong relationships with major hospital chains and leading medical facilities, ensuring the effective supply of antibiotics, antifungals, and antiviral treatments. Shekhar Aley's leadership is instrumental in translating Gufic Group's research and development successes into market penetration and revenue growth. By developing targeted sales strategies and robust marketing campaigns, Aley supports the continuous launch of advanced new products and the company's expanding international footprint. The President's deep understanding of market dynamics and customer needs ensures Gufic Group maintains its competitive edge and strengthens its position as a respected player in the pharmaceutical industry.
Rajesh Kaul - Senior President
Rajesh Kaul, the Senior President at Gufic Group, provides strategic leadership and oversight across key business functions, contributing to the company's overall growth and market presence. Kaul's extensive experience guides the development and execution of strategies that enhance Gufic Group's reputation for innovative and high-quality pharmaceutical and herbal products. This senior leadership role involves fostering collaborations that support the company's position as one of India's largest manufacturers of lyophilized injections, ensuring the consistent supply of critical treatments like antibiotics, antifungals, and antivirals to major hospital chains. Rajesh Kaul plays a vital part in advancing Gufic Group's commitment to research and development, facilitating the continuous launch of advanced new products. By offering broad strategic direction, Kaul supports the expansion of the company's international footprint and reinforces its market leadership. The Senior President's influence is crucial in navigating complex market landscapes and driving sustained success for Gufic Group.
Rajeev Agarwal - President
Rajeev Agarwal, the President at Gufic Group, directs strategic initiatives that propel the company's expansion and market influence. Agarwal's leadership focuses on enhancing Gufic Group's portfolio of innovative pharmaceutical and herbal products, reinforcing its status as a leading manufacturer of lyophilized injections. This role involves overseeing market development strategies and strengthening relationships with key stakeholders, including major hospital chains and leading medical facilities across India. Rajeev Agarwal is pivotal in driving the company's commitment to research and development, supporting the continuous introduction of advanced new products and the expansion of its international footprint. By providing executive direction, Agarwal ensures that Gufic Group effectively meets the evolving needs of the healthcare sector and maintains its competitive advantage. The President's vision is essential for guiding the company's trajectory and achieving its long-term objectives in the global pharmaceutical market.
Sunil Desai - Chief Human Resources Officer
Sunil Desai, the Chief Human Resources Officer at Gufic Group, architects the human capital strategy, fostering a culture of innovation and excellence. Desai oversees talent acquisition, development, and retention programs, ensuring Gufic Group attracts and retains top talent essential for its pharmaceutical and herbal product manufacturing. This leadership position involves cultivating an environment that supports research and development, crucial for the continuous launch of advanced new products. Sunil Desai's focus on employee engagement and organizational development is key to maintaining the high standards required for producing lyophilized injections and supplying major hospital chains across India. By developing robust HR policies and initiatives, Desai ensures the workforce is equipped to meet the demands of a dynamic industry and support the company's expanding international footprint. The CHRO's strategic guidance is vital for aligning employee efforts with Gufic Group's mission and driving operational success through its people.
Explore Leadership Teams in Manufacturing
Johnson & Johnson is a global healthcare company that develops pharmaceuticals and medical technologies. It provides innovative medicines, surgical products, and medical devices used in areas such as oncology, immunology, neuroscience, and cardiovascular care, serving healthcare providers and patients worldwide.
Company Leadership
DB
CC
RD
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Company Leadership
SR
Founded in 1974, Apotex is a proud Canadian, global pharmaceutical company that produces high-quality, affordable medicines (both generic and innovative pharmaceuticals) for patients around the world.
Company Leadership
MG
FT
CV
Dexcel Pharma is Israel’s largest privately owned pharmaceutical company, founded in 1968 and headquartered in Or Akiva. It develops, manufactures, and commercializes value‑added branded prescription drugs, generics, and OTC products—primarily oral solid dosage forms—supplying more than 85 products in over 175 dosage forms to markets including the U.S., U.K., Germany, Austria, and others through subsidiaries and distribution partners.
Company Leadership
UE
EH
Frequently Asked Questions Regarding Gufic Group Top Executives and Leadership Team
